Picard / SynCardia Featured on the Cruxx of MedTech Podcast
Rhea-AI Summary
Picard Medical (NYSE American: PMI) announced on Jan 13, 2026 the launch of a Cruxx to MedTech podcast series focused on the SynCardia Total Artificial Heart (STAH) and the next‑generation fully implantable Emperor device.
The series features a patient survival story and an interview with CEO Patrick NJ Schnegelsberg, who outlines the STAH platform, differentiation versus other approaches, the Company's long‑term vision as an alternative to transplantation, and the commercial opportunity from global donor heart shortages.
The podcast is available for download and streaming on Apple Podcasts, Spotify, Google Podcasts and via Cruxx's website.
Positive
- None.
Negative
- None.
News Market Reaction – PMI
In the Jan 13 session, PMI gained 4.82%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Conference participation | Positive | +10.4% | Management attendance at JPM week conferences and investor meetings. |
| Jan 06 | Product rollout | Positive | +3.6% | Rollout of FDA-cleared CPC1 Connector Covers for the STAH system. |
| Dec 30 | Governance/leadership | Positive | -6.4% | CEO elected to AZBio Board, underscoring ecosystem engagement. |
| Dec 24 | Debt financing | Negative | -1.9% | Announcement of up to $50M senior secured notes and warrants. |
| Dec 18 | Listing milestone | Positive | +10.3% | NYSE opening bell event marking public company milestone. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Operational and visibility-focused news (product updates, listings, conferences) have often coincided with positive next-day moves, while governance or financing items have shown more mixed reactions.
Over the past month, Picard has highlighted its transition to the public markets by ringing the NYSE opening bell on Dec 18, 2025, introduced up to $50M in senior secured debt financing due 2028, and reported the CEO’s election to the AZBio board through Dec 2028. Early January news focused on rollout of an FDA-cleared STAH accessory and investor-facing conference participation. The new MedTech podcast appearance continues this pattern of emphasizing platform visibility and commercialization potential.
Key Terms
total artificial heart medical
u.s. fda regulatory
health canada regulatory
end stage heart failure medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the launch of the Cruxx to MedTech Podcast discussing series exploring the SynCardia Total Artificial Heart (STAH) and the next generation, fully implantable Emperor device through the lens of patients and management.
Anchored by a powerful patient survival story, the series highlights the real-world impact of the STAH on patients facing end stage heart failure. The discussion then turns to SynCardia System’s / Picard Medical’s CEO, Patrick NJ Schnegelsberg who outlines the Company’s STAH platform and its next generation fully implantable Emperor system. Management highlights the clear differentiation of STAH compared to other approaches, the Company’s long-term vision to create a true alternative to heart transplantation, and the significant commercial opportunity driven by the global shortage of donor hearts.
The podcast will be available for download and streaming on all major platforms, including Apple Podcasts, Spotify, and Google Podcasts and available directly on Cruxx’s website here: https://www.thisiscruxx.com/content-hub/
About Cruxx
Cruxx is a medical technology search and capital advisory firm on a mission to place MedTech pioneers in transformative roles that help people live longer. With a focus on critical fields such as cardiovascular, surgical robotics, neurotechnology, AI, and digital health, Cruxx partners with founders, executives, and investors to build leadership teams and accelerate life-changing innovation. For information, visit: www.thisiscruxx.com
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
